Analyst Charles Zhu of LifeSci Capital maintained a Buy rating on Zymeworks (ZYME – Research Report), retaining the price target of $30.00.
Charles Zhu has given his Buy rating due to a combination of factors that highlight Zymeworks’ promising position in the market. The company’s lead candidate, zanidatamab, has shown impressive results in single-arm studies, demonstrating higher objective response rates and median duration of response compared to existing treatments like trastuzumab. This suggests that zanidatamab could potentially offer a best-in-class profile, especially as it heads into the second half of 2025 with anticipated topline data.
Moreover, Zymeworks’ strategic focus on the HER2+ PD-L1+ subset, where zanidatamab’s efficacy appears robust, positions it well against competitors. The company’s financials, including a manageable cash burn and a solid cash runway, further support its capacity to advance its clinical programs. These elements collectively underpin Zhu’s confidence in Zymeworks’ potential for growth and justify the Buy rating.
In another report released on March 6, Stifel Nicolaus also maintained a Buy rating on the stock with a $28.00 price target.